Arcus Biosciences Inc

Research Arcus Biosciences Inc (RCUS) on Bullrun: market cap USD 3.91B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRCUS
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 3.91B
• Financial periodFY2025
• RevenueUSD 33.00M
• Revenue growth-35.3%
• Net income-USD 353.00M
• Free cash flow-USD 484.00M

Valuation Snapshot

latest market cap is USD 3.91B.

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Frequently asked questions

What is Arcus Biosciences Inc's market cap?

Arcus Biosciences Inc's market capitalization is USD 3.91B.

What does Arcus Biosciences Inc do?

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer;